Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 13

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 13
---
RA) since April 2023; member of the board of directors for NextGenNK since June 2019; member of the board of directors
or special advisor to the board of BioFlorida since January 2019, and a member of the Society for Natural Immunity since July 2018.
Mr. Calder has more than 30 years of life science executive experience, having served in various senior executive roles for Florida-based
biotechnology companies and research institutes including Viragen, Accentia Biopharmaceuticals, Biovest International and the Vaccine
& Gene Therapy Institute of Florida, as well as having formerly served as a registered financial portfolio manager with a focus on
life science equities with the New York Stock Exchange member firms, Gruntal & Co. and Dean Witter Reynolds. Mr. Calder received a
BA from Florida State University.

Mark A. Collins, PHD

Dr. Collins has dedicated his 40-year career to leveraging
computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies,
leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since
2022, a company that takes a unique AI-driven clinically informed, network-medicine approach to repurposing existing drugs for acute and
chronic neuropathic pain conditions. Prior to that time, Dr. Collins was the VP Translational Services at Icometrix, where he
led the strategy to drive the adoption of AI assisted MRI and digital health tools to help Pharma improve the translational success of
CNS therapies for a range of neurodegenerative diseases, such as Multiple Sclerosis, Alzheimer’s, and Parkinson’s. Prior to
Icometrix, from 2017 to 2021, Dr. Collins was at Helomics, Corp., most recently as its Chief Technology Officer, where he drove the technical
development and commercial realization of AI-driven predictive models of tumor drug response and clinical outcome into
the research and clinical decision support markets. Dr. Collins is also the founder and principal consultant of Purplebio Consulting,
LLC, a life science consultancy, offering scientific, market, product strategy consulting as well as tactical execution. Dr. Collins holds
a doctorate of Philosophy in Microbiology from the University of Surrey and a Bachelor of Science in Applied Sciences from University
of Wolverhampton.

James A. McNulty

Mr. McN